Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation – The phase 3 randomized clinical ClarIDHy trial
This is the report of final overall survival (OS) results from the randomized phase 3 ClarIDHy trial, [...]
Read moreSafety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I/II study
This is the report of a randomized phase 1/2 study assessing the safety and efficacy of tremelimumab (T; [...]
Read more
ILCA Webinar: Primary and acquired resistance to immunotherapy in HCC: from research to practice and viceversa
11 November, 2021 at 05:30 PDT / 08:30 EDT / 14:30 CET / 20:30 UTC+8
Read moreILCA Webinar: Systemic therapy of CCA. Patho-molecular profile meets treatment choices
27 September, 2021 at 05:30 PDT / 08:30 EDT / 14:30 CET / 20:30 UTC+8
Read more